Mounjaro®
Starting from £179.99/mo
Start journey Learn moreReading the Wegovy dose ladder correctly, and what the chart actually tells you
The biggest myth: bigger pen equals better treatment
A common misreading of the Wegovy sizes chart is that a higher dose number means a more effective or more serious medicine. It does not. The dose ladder is a tolerability tool. Your gut needs time to adapt to semaglutide's effect on gastric emptying, and moving up too fast almost guarantees nausea and vomiting that would cause many people to abandon treatment altogether.
The 0.25 mg pen, which you use for the first four weeks, is not treating anything in a meaningful way yet. It is setting your system up so that 0.5 mg lands more gently, and so on through each rung. Clinical trials like STEP 1, published in the New England Journal of Medicine, were built around this escalation pattern, participants reached 2.4 mg over roughly 16–20 weeks, and that is the schedule reflected in the licensed dosing pathway.
If the chart in front of you implies all five (or six) pens are interchangeable choices, it is oversimplifying. Your prescriber works through the schedule with you; patients do not select a dose themselves from a menu. That is the point of clinical oversight, not a bureaucratic obstacle.
The six Wegovy pen sizes, laid out plainly
Here is what the UK-licensed schedule actually looks like, drawn from the Wegovy Summary of Product Characteristics on the eMC:
| Phase | Dose | Duration | Purpose |
|---|---|---|---|
| Initiation | 0.25 mg | 4 weeks | Tolerability, body adjustment |
| Escalation | 0.5 mg | 4 weeks | Gradual increase in efficacy |
| Escalation | 1.0 mg | 4 weeks | Continued escalation |
| Escalation | 1.7 mg | 4 weeks | Approaching maintenance range |
| Maintenance | 2.4 mg | Ongoing (up to 2 years on NHS) | Standard maintenance dose |
| Higher maintenance | 7.2 mg | Ongoing, prescriber-led | MHRA-approved April 2026; BMI ≥30 only |
A practical note: the 7.2 mg dose was approved by the MHRA on 14 April 2026 for adults with a BMI of 30 or above. It is not simply three 2.4 mg pens added together, it is a distinct licensed maintenance dose, and the route to it still starts at 0.25 mg with the same step-by-step titration. Trials reported roughly 20.7% average weight reduction over 72 weeks at this higher dose, which narrows the gap with tirzepatide's headline results. Whether that dose is right for any individual is a prescriber's call.
For more on how the wider semaglutide schedule sits within a weight-management plan, the semaglutide overview covers the mechanism and evidence.
What changes between doses, and what does not
The pen format stays the same at every level: pre-filled, once-weekly, subcutaneous. You rotate injection sites between your abdomen, thigh and upper arm. Storage follows the same refrigeration requirement across all pens (2–8°C), with a limited room-temperature window, the exact number of hours is in your Patient Information Leaflet and should not be guessed from a chart online.
Side effects are most common at the start of treatment and after each dose increase. Nausea, loose stools, reduced appetite and occasional vomiting tend to settle within the first couple of weeks at a new level. That is precisely why the chart is designed as a ladder rather than a leap. Anyone experiencing severe, persistent stomach pain (particularly if it spreads to the back) should seek medical attention promptly; this is one of the signs highlighted by NHS guidance.
If you are comparing Wegovy pen sizes against other GLP-1 medicines, the Wegovy dose comparison page and the broader semaglutide dosing chart set out the numbers side by side. The Wegovy weight-loss chart covers what the clinical trial data shows at each maintenance dose for context on expected outcomes.
Does the dose on the chart tell you what you will lose?
Not directly, and this is where many readers trip up. The sizes chart tells you the schedule; it does not predict your individual outcome. STEP 1 trial participants at 2.4 mg averaged around 15% body-weight reduction over 68 weeks, but individual results varied. Participants at 7.2 mg averaged around 20.7% in subsequent trials. Both figures come from specific conditions: alongside a reduced-calorie diet and increased physical activity, with careful dose escalation and clinical support throughout.
There is also cost to factor in. Wegovy pricing varies by dose and provider; understanding the full-schedule cost helps with planning, particularly once you reach and sustain the maintenance dose. Worth looking at before you start.
The chart is a map, not a destination. Our prescribers at nume review every patient individually before confirming a starting dose and monitoring progress through each increase. If you would like to understand which part of the Wegovy schedule might apply to your situation, speak to our prescribers, the consultation is free, and the review happens the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.